Xia Jiasheng – CEO, Guangdong Medical Valley
First set up in 2014, the Guangdong Medical Valley is an investment incubation platform in southern China focusing on the biomedical and medical device industries. CEO Xia Jiasheng explains how…
Company information:
Ming Wai Lau Centre for Reparative Medicine is established to further accelerate research in stem cell biology, biomedical engineering, biotechnology, and regenerative medicine at Karolinska Institutet. By building a front line technology focused hub in Hong Kong, Karolinska Institutet can further strengthen the scientific interactions between KI and the Hong Kong and Chinese scientific communities.
Address: 6F, Building 15W, Hong Kong Science Park, Shatin, New Territories, Hong Kong
Tel.: +852 2624 3807
Website: http://ki.se/en/research/about-ming-wai-lau-centre-for-reparative-medicine
Email: emily.ip@ki.se (Head of Administration)
First set up in 2014, the Guangdong Medical Valley is an investment incubation platform in southern China focusing on the biomedical and medical device industries. CEO Xia Jiasheng explains how…
Fresh from the news that one of its AI-designed and discovered drug candidates has entered Phase II human clinical trials – the first time that such a project has made…
The Guangzhou production site of HKEX-listed RNA therapeutics biotech Sirnaomics is overseen by pharma industry veteran Edward Wang. Here, Wang explains his contribution to the development of good manufacturing practices…
Lawrence Wong outlines how reproductive medicine-focused Ferring Pharmaceuticals is serving the patients of Hong Kong as the city’s birth rates have plateaued, weighs in on why the establishment of a…
Bio-Gene, part of the Pangenia Group, is one of Hong Kong’s most notable life science success stories, with operations in the laboratory supply of instruments, reagents and consumables. Desmond Hau,…
Dr Brian CHUNG Hon-Yin, Chief Scientific Officer at the Hong Kong Genome Institute (HKGI) and Clinical Associate Professor at the University of Hong Kong (HKU) discusses the creation of the…
Leveraging his 24-year career in Big Pharma, Howard Lin recently moved to set up healthcare and life science consultancy CL Consultancy in Hong Kong. Lin examines the opportunities and challenges…
2023 got off to a good start for Boehringer Ingelheim’s human pharma division. Not only has the year begun with substantial sales growth thanks to the German firm’s diabetes and…
Looking ahead to the Hong Kong International Biotechnology Convention (BIOHK2023) taking place between 13-16 September 2023 at the Hong Kong Convention and Exhibition Centre, three of the event’s leading lights…
Henry Yau is managing director of the Hong Kong University (HKU) Clinical Trials Centre in Hong Kong and CEO of the Centre’s mainland China arm. Yau explains how the clinical…
MSD’s managing director for Hong Kong and Macau, Vincent Tong, came to lead the affiliate during the COVID-19 pandemic. He outlines the challenges and opportunities of a challenging time, discusses…
Executive director & chief strategy officer at HKEX-listed RNA therapeutics biotech Sirnaomics, Dr Dai Xiaochang is no stranger to Hong Kong and mainland China’s pharma and biotech ecosystem, having held…
See our Cookie Privacy Policy Here
